TREATMENT OF COGNITIVE IMPAIRMENT

• US 20170119704A1
• Filed: 10/13/2016
• Published: 05/04/2017
• Est. Priority Date: 10/13/2015
• Status: Abandoned Application

• Current Assignee: Ovid Therapeutics Inc.
• Original Assignee: Ovid Therapeutics Inc.
• Inventors: DURING, Matthew
• Application Number:
  US15/292,660
• Publication Number:
  US 20170119704A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/15 Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system

Abstract

Provided are methods of treating cognitive impairment and/or psychosis and/or movement disorders by administering a pharmaceutical composition of eplivanserin or a pharmaceutically acceptable salt thereof to a subject in need thereof.

Claims

1. A method for treating cognitive impairment comprising administering eplivanserin or a pharmaceutically acceptable salt of eplivanserin to a subject in need of such treatment.

2. The method of claim 1, wherein the cognitive impairment is characterized by a deficit in mental activities associated with thinking, reasoning, learning, memory and/or sensory processing.

3. The method of claim 2, wherein the cognitive impairment is selected from the group consisting of agnosia, amnesia, aphasia, apraxia, delirium, dementia and a learning disorder.

4. The method of claim 1, wherein the cognitive impairment is associated with a condition selected from the group consisting of AIDS dementia complex, Binswanger'"'"'s disease, Lewy-body dementia, frontotemporal dementia, mild cognitive impairment, multi-infarct dementia, Pick'"'"'s disease, semantic dementia, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Huntington'"'"'s disease, Amyotrophic Lateral Sclerosis (ALS), Creutzfeld-Jacob disease, Kuru disease, corticobasal degeneration, frontotemporal lobar degeneration, multiple sclerosis, normal pressure hydrocephalus, organic chronic brain syndrome, Pick'"'"'s disease, progressive supranuclear palsy, senile dementia, vascular dementia, autism spectrum disorder, Down Syndrome, Fragile X Syndrome, Angelman syndrome, Prader-Willi syndrome, Rett syndrome, childhood disintegrative disorder, attention deficit disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, brain trauma, infection, drug intoxication, drug abuse, sleep deprivation, anxiety disorders, dissociative disorders, mood disorders, schizophrenia, treatment with psychiatric medications, treatment with dopamine agonists, somatoform and factitious disorders and chronic pain.

5. The method of claim 1, wherein the cognitive impairment is associated with neurodegenerative disease, brain trauma, psychiatric disorders or chronic pain.

6. The method of claim 5, wherein brain trauma is selected from the group consisting of chronic subdural hematoma, concussion, intracerebral hemorrhage, encephalitis, meningitis, septicemia, drug intoxication and drug abuse.

7. The method of claim 5, wherein the psychiatric disorders are selected from the group consisting of anxiety disorders, dissociative disorders, mood disorders, schizophrenia, and somatoform and factitious disorders.

8. The method of claim 5, wherein the neurodegenerative disease is Huntington'"'"'s disease.

9. The method of claim 5, wherein the neurodegenerative disease is Parkinson'"'"'s disease.

10. The method of claim 5, wherein the neurodegenerative disease is Amyotrophic lateral sclerosis.

11. The method of claim 5, wherein the neurodegenerative disease is Alzheimer'"'"'s disease.

12. The method of claim 5, wherein the neurodegenerative disease is Lewy-body dementia.

13. The method of claim 1, wherein eplivanserin or a pharmaceutically acceptable salt of eplivanserin is administered from one to three times a day.

14. The method of claim 13, wherein from 1 mg to 50 mg of eplivanserin or a pharmaceutically acceptable salt of eplivanserin is administered within a 24 hour period.

15. A method for treating cognitive impairment comprising administering eplivanserin or a pharmaceutically acceptable salt of eplivanserin to a subject in need of such treatment, wherein the cognitive impairment is characterized by a deficit in mental activities associated with thinking, reasoning, learning, memory and/or sensory processing and the cognitive impairment is selected from the group consisting of agnosia, amnesia, aphasia, apraxia, delirium, dementia and a learning disorder and the cognitive impairment is associated with a condition selected from the group consisting of AIDS dementia complex, Binswanger'"'"'s disease, Lewy body dementia, frontotemporal dementia, mild cognitive impairment, multi-infarct dementia, Pick'"'"'s disease, semantic dementia, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Huntington'"'"'s disease, Amyotrophic Lateral Sclerosis (ALS), Creutzfeld-Jacob disease, Kuru disease, corticobasal degeneration, frontotemporal lobar degeneration, multiple sclerosis, normal pressure hydrocephalus, organic chronic brain syndrome, Pick'"'"'s disease, progressive supranuclear palsy, senile dementia, vascular dementia, autism spectrum disorder, Down Syndrome, Fragile X Syndrome, Angelman syndrome, Prader-Willi syndrome, Rett syndrome, childhood disintegrative disorder, attention deficit disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, brain trauma, infection, drug intoxication, drug abuse, sleep deprivation, anxiety disorders, dissociative disorders, mood disorders, schizophrenia, somatoform and factitious disorders and chronic pain, wherein the eplivanserin or a pharmaceutically acceptable salt of eplivanserin is administered from one to three times a day and from 1 mg to 50 mg of eplivanserin or a pharmaceutically acceptable salt of eplivanserin is administered within a 24 hour period.

16. A method of treating Lewy-body dementia in a patient diagnosed with a cognitive disorder comprising administering eplivanserin or a pharmaceutically acceptable salt thereof.

17. A method of treating psychosis comprising administering eplivanserin or a pharmaceutically acceptable salt thereof to a patient in need thereof.

18. A method of treating Parkinson'"'"'s disease psychosis comprising administering eplivanserin or a pharmaceutically acceptable salt thereof to a patient in need thereof.

19. A method of treating Alzheimer'"'"'s disease psychosis comprising administering eplivanserin or a pharmaceutically acceptable salt thereof to a patient in need thereof.